Curriculum Vitae
1. Personal details:
Name: Karl Lenhard Rudolph
Academic title: Prof. Dr. med.
Position:Full Professor
Date of birth:18.01.1969
Nationality: German
Institution: University of Ulma Department of Molecular Medicine and Max-Planck-Research-Group on Stem Cellging
Address:Albert-Einstein-Allee 11, 89081 Ulm, Germany
Telefon:0049-731-50-36100
Fax:0049-731-50-36102
E-mail:Lenhard.Rudolph@Uni-Ulm.de
Private address: Adolf Reichwein Weg 14, 89075 Ulm, Germany
Marital status: married to Masami Rudolph
Publications: 64
2. Career progression:
1988-1989 Study of Biology at the Georg-August iversity, Göttingen
1989-1995 Medical School at the Georg-August-University, Göttingen Medical thesis in hematology and oncology (Prof. Dr. med. W. Hiddemann): Pharmakokinetic and cellular uptake of d,l-Leukovorin and l-Leukovorin
1996-1997 Civil service as a medical doctor in training (AiP) in the Department of Gastroenterology, Hepatology and Endocrinology (Prof. Dr. med. M.P. Manns), Medical School Hannover
1997 Licence to practice medicine
1998 Postdoctoral studies funded by the DFG in the laboratory of Prof. R.A. DePinho, Department of Microbiology, Albert-Einstein-College of Medicine, Bronx, New York, U.S.A. and later at the Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA, U.S.A.
2001-2006 Research group leader in the Department of Gastroenterology, Hepatology and Endokrinology, Medical School Hannover, funded by the Emmy-Noether-Program of the DFG
2003 Habilitation in „Experimental Gastroenterology: “The role of telomere shortening during aging, regeneration and carcinogenesis
2003 Research award of the German Association for the Study of Liver Disease (GASL)
2004 Research award of the Roggenbuck-foundation for Cancer Research in Northern Germany
2005 Research award of the GlaxoSmithKline foundation for “basic medical research”
2006 Research award of the Berlin-Brandenburgischen Akademie for Cancer Research
11/2006 Named professorship of the DFG (Heisenberg) for Research on Stem Cell Aging, Regeneration, and Carcinogenesis
9/2007 Chairman of the Department of Molecular Medicine and the Max-Planck-Research-Group on Stem cell Aging at Ulm University
3/2008 Guest Professor and partner of the Max-Planck-Partner-Group on “Stem Cell Aging” at the Institute of Laboratory Animal Sciences (ILAS) at the Chinese Academy of Medical Sciences (CAMS) in Bejing, China
Full publication list
A.) Original paper:
1. Rudolph KL, Chang S, Lee H-W, Blasco M, Gottlieb GJ, Greider C, and DePinho RA. Longevity, stress response and cancer in aging telomerase deficient mice. Cell 1999; 96:701-712.
2. Rudolph KL, Trautwein C, Kubicka S, Rakemann T, Bahr MJ, Sedlacek N, Schuppan D, and Manns MP. Differential regulation of extracellular matrix synthesis during liver regeneration in rats. Hepatology 1999; 30:1159-66.
3. Kubicka S, Kuhnel F, Zender L, Rudolph KL, Plumpe J, Manns MP, Trautwein C. p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis. J. Biol. Chem. 1999; 274:32137-44.
4. Schleyer E, Rudolph KL, Braess J, Unterhalt M, Ehninger G, Hiddemann W, Kern W. Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. Cancer Chemother. Pharmacol. 2000; 45:165-71.
5. Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000; 287:1253-8.
6. Kubicka S, Rudolph KL, Hanke T, Tietze MK, Tillmann HL, Trautwein C, Manns M. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver 2000; 20:312-318.
7. Wong KK, Chang S, Weiler SR, Ganesan S, Chaudhura J, Zhu C, Artandi SE, Rudolph KL, Gottlieb GJ, Chin L, Alt FW, DePinho RA. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat. Genet. 2000; 26:85-8.
8. Kubicka S, Kuhnel F, Flemming P, Hain B, Kezmic N, Rudolph KL, Manns M, Meier PN. K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut 2001; 48:403-8.
9. Lee KH, Rudolph KL, Ju YJ, Greenberg RA, Cannizzaro L, Chin L, Weiler SR, DePinho RA. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci U S A. 2001; 98:3381-3386.
10. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 2001; 28:155-9.
11. Ranganathan V, Heine WF, Ciccone DN, Rudolph KL, Wu X, Chang S, Hai H, Ahearn IM, Livingston DM, Resnick I, Rosen F, Seemanova E, Jarolim P, DePinho RA, Weaver DT. Rescue of a telomere length defect of Nijmegen breakage syndrome cells requires NBS and telomerase catalytic subunit. Curr. Biol. 2001; 11:962-6.
12. Hemann MT, Rudolph KL, Strong MA, DePinho RA, Chin L, Greider CW. Telomere dysfunction triggers developmentally regulated germ cell apoptosis. Mol. Biol. Cell 2001; 12:2023-30.
13. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001; 48:783-9.
14. Kubicka S, Claas C, Staab S, Kuhnel F, Zender L, Trautwein C, Wagner S, Rudolph KL, Manns M. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci. 2002; 47:114-21.
15. Omata M, Dan Y, Daniele B, Plentz R, Rudolph KL, Manns M, Piratvisuth T, Chen DS, Tateishi R, Chutaputti A. Clinical features, etiology, and survival of hepatocellular carcinoma among different countries. J Gastroenterol Hepatol. 2002; 17:S40-9
16. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, Klempnauer J, Flemming P, Franco S, Blasco MA, Manns MP, Rudolph KL. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 2002; 16:935-42.
17. Watabe-Rudolph M, Rudolph KL, Averbeck T, Buhr T, Lenarz T, Stover T. Telomerase Activity, Telomere length, and apoptosis: a comparison between acquired cholesteatoma and squamous cell carcinoma. Otol Neurotol. 2002; 23:793-8.
18. Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, Manns M, Kubicka S, Kuhnel F. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 2003; 63:3181-8
19. Satyanarayana A, Wiemann SU, Buer J, Lauber J, Dittmar KE, Wustefeld T, Blasco MA, Manns MP, Rudolph KL. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J. 2003; 22:4003-4013
20. Plentz RR, Wiemann SU, Flemming P, Meier PN, Kubicka S, Kreipe H, Manns MP, Rudolph KL. Telomere shortening of epithelial cells characterises the adenoma-cacrinoma transition of human colorectal cancer. Gut 2003; 52:1304-7.
21. Farazi PA, Glickmann J, Jiang S, Yu A, Rudolph KL &DePinho RA. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res. 2003; 63:5021-5027.
22. Schaetzlein S, Lucas-Hahn A, Lemme E, Kues WA, Dorsch M, Manns MP, Niemann H, Rudolph KL. Telomere length is reset during early embryogenesis. Proc Natl Acad Sci U S A. 2004; 101:8034-8.
23. Satyanarayana A, Greenberg RA, Schaetzlein S, Buer J, Masutomi K, Hahn WC, Zimmermann S, Martens U, Manns MP, Rudolph KL. Mitogen stimulation co-operates with telomere shortening to activate DNA-damage responses and senescence signaling. Mol. Cell Biol. 2004; 24:5459-74.
24. Plentz RR, Caselitz M, Bleck JS, Gebel M, Flemming P, Kubicka S, Manns MP, Rudolph KL. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatocellular carcinoma. Hepatology 2004; 40:80-6
25. Satyanarayana A, Geffers R, Manns MP, Buer J, Rudolph KL. Gene expression profile at the G1/S transition after partial hepatectomy in mice. Cell Cycle 2004; 3:1405-17.
26. Wiemann SU, Satyanarayana A, Buer J, Kamino K, Manns MP, Rudolph KL. Contrasting effects of telomere shortening on organ homeostasis, tumor suppression, and survival during chronic organ damage. Oncogene. 2005, 24:1501-9.
27. Lechel A, Satyanarayana A, J u Z, Plentz RR, Schaetzlein S, Rudolph C, Wilkens L, Wiemann SU, Saretzki G, Malek NP, Manns MP, Buer J and Rudolph KL. The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo. EMBO Rep. 2005, 6:275-81.
28. Plentz RR, Lankisch TO, Basturk M, Muller CC, Kirchhoff T, Gebel M, Bleck JS, Kubicka S, Manns MP, Meier PN, Rudolph KL. Prospective analysis of german patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization with or without prophylactic antibiotic therapy. J Gastroenterol Hepatol. 2005, 20:1134-6.
29. Wirth T, Kuhnel F, Fleischmann-Mundt B, Woller N, Djojosubroto M, Rudolph KL, Manns M, Zender L, Kubicka S. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res. 2005, 65:7393-402.
30. Plentz RR, Tillmann HL, Kubicka S, Bleck JS, Gebel M, Manns MP, Rudolph KL. Hepatocellular carcinoma and octreotide: Treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage. J Gastroenterol Hepatol. 2005; 20:1422-8.
31. Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, Harley CB, Rudolph KL. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 2005, 42:1127-36.
32. Plentz RR, Schlegelberger B, Flemming P, Manns MP, Rudolph KL*, Wilkens L. Telomere shortening correlates with increasing aneuploidy of chromosome 8 on a cellular level in primary human hepatocellular carcinoma. *Co-Corresponding author, Hepatology 2005; 42:522-6.
33. Kirchhoff TD, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, Kubicka S, Galanski M, Manns MP, Schild H, Gallkowski U. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol. 2006, 32:201-7.
34. Choudhury RA, Ju Z, Djojosubroto MW, Schienke A, Lechel A, Schaetzlein S, Jiang H, Stepczynska A, Wang C, Buer J, Lee HW, von Zglinicki T, Ganser A, Schirmacher P, Nakauchi H, Rudolph KL. p21-deletion prolongs lifespan of telomere dysfunctional mice without accelerating cancer formation. Nat Genet. 2007; 39:99-105.
35. Plentz RR, Park YN, Lechel A, Kim H, Nellessen F, Langkopf BHE, Wilkens L, Destro A, Fiamengo B, Manns MP, Roncalli M, Rudolph KL. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 2007, 45:968-76.
36. Lechel A, Holstege H, Begus Y, Schienke A, Kamino K, Lehmann U, Kubicka S, Schirmacher P, Jonkers J, Rudolph KL. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology 2007, 132:1465-75.
37. Ju Z, Jiang H, Jaworski M, Rathinam C, Gompf A, Klein C, Trumpp A, Rudolph KL. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat Med. 2007; 13:742-7.
38. Schaetzlein S, Kodandaramireddy NR, Ju Z, Lechel A, Stepzynska A,Lilli DR, Clark AB, Rudolph C, Kuhnel F, Wei K Schlegelberger B, Schirmacher P, Kunkel TA, Greenberg RA, Edelmann W, Rudolph KL. Exo1 deletion impairs DNA damage signalling and prolongs lifespan of telomere dysfunctional mice. Cell 2007, 130:863-77.
39. Templin C, Kotlarz D, Rathinam C, Rudolph C, Schätzlein S, Ramireddy K, Rudolph KL, Schlegelberger B, Klein C, Drexler H. Establishment of immortalized multipotent hematopoietic progenitor cell lines by retroviral-mediated gene transfer of beta-catenin. Exp Hematol. , 36:204-15.
B.) Reviews and book chapter:
40. Kubicka S, Rudolph L, Manns MP. [Hepatocellular carcinoma: diagnosis and multi-modality therapy]. Internist (Berl) 1997; 38:954-62.
41. KL Rudolph and RA DePinho. Telomeres and telomerase in experimental liver cirrhosis. In: Biology and Pathobiology of the Liver, Editors: I Arias, F Chisari Edts. 2001; 4th Edt.:1001-1010.
42. Djojosubroto MW, Choi YS, Lee HW, Rudolph KL. Telomeres and telomerase in aging, regeneration and cancer. Mol. Cells 2003; 15:164-75.
43. A. Satyanarayana, K.L. Rudolph. p16 and ARF: activation of teenage proteins in old age. J. Clin. Invest. 2004;114:1237-
44. Satyanarayana A, Manns MP, Rudolph KL. Telomeres, telomerase and cancer: an endless search to target the ends. Cell Cycle 2004; 3:1138-50.
45. A. Satyanarayana, M.P. Manns, K.L. Rudolph. Telomeres and telomerase: a dual role in carcinogenesis. Hepatology 2004; 40:276-283.
46. Lechel A, Manns MP, Rudolph KL. Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma. J. Hepatol. 2004; 41:491-7.
47. Nisar P. Malek, K. Lenhard Rudolph. Control of liver cell proliferation, in: Textbook of Hepatology, 3rd edition, Editors: JP Benhamou, JF Dufour, A Blei, et al. 2006, 2.5.1.
48. Rudolph KL. Telomeres and telomerase influence the course of human diseases, aging and carcinogenesis. Curr. Mol. Med. 2005; 5:133-4.
49. R. Greenberg and K.L. Rudolph. Telomere structural dynamics in genome integrity control and carcinogenesis. In: Genome Instability in Cancer Development, Series: Advances in Experimental Medicine and Biology, Vol. 570, Nigg, Erich A. (Ed.) ,2005, XV, 511 p.
50. A. Satyanarayana, M.P. Manns, K.L. Rudolph. Telomeres and telomerase in liver regeneration and carcinogenesis. In: Signaling Pathways in Liver Diseases, Editors: J.F. Dufour., P.A. Clavien 2006, 333-339.
51. H.L. Tillmann, M.P. Manns, K.L. Rudolph. Merging models of hepatitis C virus pathogenesis. Semin Liver Dis. 2005; 25:84-92.
52. S. Schaetzlein, K.L. Rudolph. Telomere length regulation during cloning, embryogenesis and aging. Reproduction, Fertility and Development 2005;17:85-96.
53. Rudolph K.L., Tillmann H.L.. Hepatitis C infection in the elderly. Aging Health 2005; 1:409-417.
54. Ju Z, Rudolph KL. Telomeres and telomerase in cancer stem cells. European Journal Cancer 2006, 42:1197-203.
55. Ju Z, Rudolph KL. Telomeres and telomerase in stem cells during aging, disease and transformation. Genome Dynamics 2006, Vol1: 84-103
56. Plentz R, Rudolph KL. Telomere und Telomerase: pathogentische Bedeutung. Deutsche Medizinische Wochenzeitschrift 2006, 131:2087-2090
57. Ju Z, Choudhury AR, Rudolph KL. A dual role of p21 in stem cell aging. Ann N Y Acad Sci. 2007, 1100:333-44.
58. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007,132:2557-76.
59. Excecuting Editor for a monography on „Mechanisms of stem cell ageing“, Springer Publishing 2008
60. Ju Z, Rudolph KL. Telomere dysfunction and stem cell ageing. Biochimi 2007, 90:24-32.
61. Jiang H, Ju Z, Rudolph KL. Telomere shortening and ageing. Z Gerontol Geriatry 2007; 40:314-324.
62. Andre Lechel, K. Lenhard Rudolph. Rho GTPases and Wnt signalling in liver cancer. Gastroenterology, 2008, in press.
63. Hashem B. El-Serag MD, Jorge Marrero, Lenhard Rudolph, K.Rajender Reddy. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology 2008, in press.
64. Hans L. Tillmann, Ruben R. Plentz, Andre Lechel, K. Lenhard Rudolph. Telomeres and telomerase in liver disease and cancer. In: Biology and Pathobiology of the Liver, Editors: I Arias, F Chisari Edts. 2001; 5th Edt.: in preparation
|
